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Abstract
Background: Cough variant asthma (CVA) is a cause of chronic cough and a precursor of typical
asthma. We retrospectively examined the longitudinal change in bronchial responsiveness and
cough reflex sensitivity in CVA patients with respect to the effect of long-term inhaled
corticosteroids (ICS).
Methods: Provocative concentration of methacholine causing a 20% fall in forced expiratory
volume in one second (PC20-FEV1) and provocative concentration of capsaicin eliciting 5 or more
coughs (C5) were measured before treatment and during a follow up period following relief of
cough (median; 2.0 (range; 0.5 to 8.0) years after the initial visit) in a total of 20 patients with CVA
(7 males and 13 females, mean ± SD age of 49.9 ± 12.9 years).
Results: Three of 8 patients not taking long-term ICS developed typical asthma compared to none
of 12 patients taking ICS (p = 0.0171). PC20-FEV1 significantly (p < 0.0001) increased from 1.80
(GSEM, 1.35) to 10.7 (GSEM, 1.63) mg/ml in patients taking ICS but did not change in patients not
taking ICS [2.10 (GSEM, 1.47) compared to 2.13 (GSEM, 1.52) mg/ml]. Cough threshold did not
change in patients whether taking or not taking ICS.
Conclusion: Long-term ICS reduces bronchial hyperresponsiveness in CVA as recognized in
typical asthma. Cough reflex sensitivity is not involved in the mechanism of cough in CVA.
Background
Cough variant asthma is a well-known cause of chronic
non-productive cough as well as gastroesophageal reflux-
associated cough and post-nasal drip-induced cough [1].
Pathophysiological features of cough variant asthma [2]
appear to be similar to typical asthma, with mildly
increased bronchial responsiveness and eosinophilic
inflammation of central and peripheral airways, and a
cough responsive to bronchodilator therapy [3]. It is,
however, controversial whether cough reflex sensitivity
contributes to the cough in CVA [4-7].
Johnson [8] reported that a significant proportion of
patients diagnosed with cough variant asthma eventually
develops wheezing, sometimes severe enough to require
continuous bronchodilator therapy. Corrao et al. [3]
reported that 2 of 6 patients with cough variant asthma
began wheezing within 18 months of completing the
study. Braman [9] restudied 16 patients diagnosed with
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cough variant asthma 3 to 5 years previously, and found
that 37% of these patients manifested intermittent wheez-
ing during the study period. Therefore, as nearly 30% of
cough variant asthma patients have been demonstrated to
develop typical asthma, cough variant asthma has been
recognized as a precursor of typical asthma.
In our previous study [4], long-term inhaled corticoster-
oids (ICS) prevented the development of typical asthma
from cough variant asthma. In another of our studies [5],
longitudinal decline in pulmonary function in cough var-
iant asthma was not different from that in healthy subjects
and inhaled corticosteroids had no effect on the pulmo-
nary function decline in cough variant asthma. However,
it is unknown 1) whether bronchial responsiveness and
cough reflex sensitivity change after relief of cough, 2)
whether inhaled corticosteroids have an beneficial effect
on bronchial responsiveness and cough reflex sensitivity,
and 3) whether bronchial responsiveness increases after
onset of typical asthma.
Although some researchers [6] reported that cough reflex
sensitivity was increased in patients with cough variant
asthma, our series of studies [4,5,7] have clearly demon-
strated that cough reflex sensitivity is within normal limits
in cough variant asthma as well as in stable typical asthma
[10]. Cough reflex sensitivity is entirely independent of
bronchial responsiveness [11] and bronchomotor tone
[12]. Furthermore, cough reflex sensitivity does not
change immediately after a patient's cough is completely
relieved on therapy within 2 months [7]. Thus, abnormal
cough reflex sensitivity is not considered to be essential in
cough variant asthma.
We examined longitudinal changes in bronchial respon-
siveness and cough reflex sensitivity and influence of ICS
on both responses in patients with cough variant asthma.
Bronchial responsiveness to methacholine and cough
reflex sensitivity to inhaled capsaicin were measured at
least two times; at the initial visit and during the follow up
period after relief of cough on treatment.
Methods
Twenty patients with cough variant asthma as a single
cause of chronic cough (median age 54 years, 7 men and
13 women), who had undertaken spirometry, bronchial
reversibility test, methacholine provocation test, capsaicin
cough provocation test, measurements of peripheral
blood eosinophil count, serum total IgE and specific IgE
to common allergens, and induced sputum eosinophil
count at presentation, were followed up with special
emphasis on typical asthma onset during 6 months or
more (median 5 years, range 0.5 – 14) (Table 1). Spirom-
etry and methacholine provocation test were repeated
during the follow up period after their cough was com-
pletely relieved on the treatment.
When the cough resolved on treatment with bronchodila-
tors and/or inhaled and/or oral corticosteroids, we
informed each patient that cough variant asthma is a pre-
cursor of typical asthma and induction of long-term
inhaled corticosteroids (ICS) is desirable because the
long-term therapy is recommended by many asthma
guidelines in typical asthma even if the disease severity is
mild. Long-term treatment with ICS was accepted and
taken by 12 patients but not by the other 8 patients.
The diagnosis of cough variant asthma was made accord-
ing to the following criteria proposed by Japanese Cough
Research Society [13], excluding a criterion of cough reflex
sensitivity within normal limits:
1) Isolated chronic non-productive cough lasting more
than 8 weeks
Table 1: Clinical parameters in cough variant asthma patients with and without inhaled corticosteroids
Without ICS With ICS P value Total
Age (years) 53.3 ± 14.3 47.6 ± 12.0 0.3495 49.9 ± 12.9
Gender (male/female) 2/6 5/7 0.4439 7/13
Intreval of methcholine provocations (years) 2.7 ± 1.0 3.4 ± 2.8 0.5172 3.1 ± 2.2
2.9 (1.1–4.0)* 2.0 (0.5–8.0)* 2.0 (0.5–8.0)*
Duration of illness (months) 41.5 ± 51.9 23.6 ± 31.4 0.3466 30.8 ± 40.5
10.0 (2.0–120.0)* 12.5 (2.0–108.0)* 12.0 (2.0–120)*
Cough threshold (µM) 11.1 (1.63)** 6.2 (1.59)** 0.4163 7.8 (1.40)**
PC20-FEV1 (mg/ml) 2.13 (1.52) 1.80 (1.35) 0.7464 1.93 (1.27)
FVC (% predicted) 105.4 ± 14.3 103.1 ± 19.1 0.7765 104.0 ± 17.0
FEV1 (% predicted) 97.4 ± 15.2 93.2 ± 16.4 0.5763 94.9 ± 15.7
FEV1/FVC (%) 73.3 ± 6.9 78.1 ± 6.5 0.1318 76.2 ± 6.9
*; median (range), **; geometric mean (geometric standard error of the mean).Cough 2005, 1:5 http://www.coughjournal.com/content/1/1/5
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2) Absence of a history of wheezing or dyspnea, and no
adventitious lung sounds on physical examination
3) Absence of post-nasal drip to account for the cough
4) Forced expiratory volume in one second (FEV1), forced
vital capacity (FVC), and FEV1/FVC ratio within normal
limits (FEV1 ≥80% of predicted value, FVC ≥80% of pre-
dicted value, and FEV1/FVC ratio ≥70%)
5) Presence of bronchial hyperresponsiveness (provoca-
tive concentration of methacholine causing a 20% fall in
FEV1 (PC20-FEV1) <10 mg/mL)
6) Relief of cough with bronchodilator therapy
7) No abnormal findings indicative of cough aetiology on
chest roentgenogram
All patients with cough variant asthma had been success-
fully treated with bronchodilators and/or corticosteroids,
without use of other medications such as proton pump
inhibitors and histamine H1-antagonists. Thus, cough
variant asthma was the single cause of chronic cough in all
patients studied.
The efficacy of bronchodilator therapy described above
was assessed according to the following criteria:
1) "Excellent" when cough totally resolved
2) "Good" when sleep and daytime quality of life were
improved
3) "Fairly good" when severity and frequency of cough
were somewhat decreased
4) "Poor" when cough was unchanged
An assessment of "Excellent" or "Good" was judged as
effective.
Pulmonary function, cough reflex sensitivity, and bron-
chial responsiveness were measured in that order within
two weeks of the first visit (Table 1), and then repeated
during the follow up period after each patient's cough was
completely relieved by the treatment. FVC, FEV1 and
flow-volume curves were measured using a dry wedge
spirometer (Chestac 11, Chest Co., Ltd., Tokyo, Japan).
Spirometry was performed and evaluated according to the
ATS criteria [14]. Capsaicin cough threshold (C5), a con-
centration of capsaicin solution eliciting 5 or more
coughs, was measured as an index of cough reflex sensitiv-
ity [7,10-12]. A provocative concentration of metha-
choline causing a 20% or greater fall in FEV1 from
prechallenge values (PC20-FEV1) was measured as an
index of non-specific bronchial responsiveness [15].
The onset of typical asthma was defined as wheezing and/
or dyspnoeic attack responding to bronchodilator
therapy.
Data analysis
Data excluding PC20-FEV1 and C5 were presented as
mean ± standard deviation (SD). PC20-FEV1 and C5 were
expressed as geometric mean value with geometric stand-
ard error of the mean. Differences between groups were
determined by parametric one-way analysis of variance
(ANOVA) or the χ2  test. Changes within group were
assessed using the paired t test. PC20-FEV1 and C5 were
analyzed using logarithmically transformed values. A p
value of 0.05 or less was considered significant.
Results
Typical asthma onset was recognized in 3 (37.5%) of 8
patients not taking long-term inhaled corticosteroids
(ICS) and none of 12 patients taking ICS. The prevalence
of asthma onset was significantly (p = 0.0214) different
between the groups. Details of the 3 patients who devel-
oped typical asthma are shown in Fig. 1.
Clinical parameters at initial presentation are summarized
in Table 1. Median interval between the first and the sec-
ond measurement of bronchial responsiveness was 2.9
years (range 1.1–4.0, mean (SD) 2.7 (1.0)) in the 8
patients not taking long-term ICS and 2.0 years (range
0.5–8.0, mean (SD) 3.4 (2.8)) in the 12 patients taking
long-term ICS. The follow-up period was not significantly
different between the groups. Age, gender, duration from
onset of cough to presentation, capsaicin cough thresh-
old, PC20-FEV1, FVC, FEV1 and FEV1/FVC ratio were not
different between the two groups.
PC20-FEV1 significantly (p < 0.0001) increased by 5.9
(GSEM, 1.40) times from 1.80 (GSEM, 1.35) to 10.7
(GSEM, 1.63) mg/ml in patients taking ICS, but did not
change in patients not taking ICS [by 0.97 (GSEM, 1.17)
times from 2.13 (GSEM, 1.52) to 2.10 (GSEM, 1.47) mg/
ml] (Fig. 2). PC20-FEV1 did not significantly change in
the 3 patients who developed typical asthma [from 0.68
(GSEM, 1.38) to 0.89 (GSEM, 1.81) mg/ml] (Fig. 1, Fig. 2)
or in 5 patients who did not develop typical asthma while
they were not taking ICS [from 4.23 (GSEM, 1.46) to 3.52
(GSEM, 1.42) mg/ml] (Fig. 2). Capsaicin cough threshold
(Fig. 3) or FEV1 (Fig. 4) did not change in patients
whether taking or not taking ICS.
Change in PC20-FEV1 by long-term treatment with ICS
did not correlate with duration from the onset of cough to
the induction of ICS treatment (r = 0.265, P = 0.4045)Cough 2005, 1:5 http://www.coughjournal.com/content/1/1/5
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(Fig. 5) or duration of ICS treatment (r = 0.009, p =
0.9774) (Fig. 6).
Discussion
Cough variant asthma was first described by Glauser [16].
The only presenting symptom is isolated chronic cough
responsive to bronchodilator therapy. The cough can
occur for many years as an extremely annoying symptom
interfering with work, sleep, and quality of life. Recogni-
tion of cough variant asthma is clinically important
because bronchodilator therapy is an effective antitussive
in cough variant asthma. Bronchodilators usually exert no
antitussive effect in other causes of isolated chronic cough
[17] such as post-nasal drip-induced cough, gastroesopha-
geal reflux-associated cough [17], and atopic cough [4,5].
Nearly 30% of cough variant asthma patients eventually
develop wheezing, sometimes severe enough to require
continuous treatment with bronchodilators [3-5]. In this
study, wheezing was recognized in none of 12 patients
taking long-term inhaled corticosteroid (ICS) therapy and
in 3 of 8 patients without ICS therapy. This result confirms
our previous investigation [4] that the typical asthma
onset rate was significantly lower in patients receiving ICS
therapy, suggesting the utility of long-term ICS as an
Longitudinal change in bronchial responsiveness in 3 patients with cough variant asthma who developed typical asthma while  did not taking inhaled corticosteroids Figure 1
Longitudinal change in bronchial responsiveness in 3 patients with cough variant asthma who developed typical asthma while 
did not taking inhaled corticosteroids. PC20-FEV1, provocative concentration of methacholine causing a 20% or greater fall in 
forced expiratory volume in 1 second (FEV1), was determined by a mouth tidal breathing method. Bronchial responsiveness 
was not obviously increased following onset of typical asthma. ICS, inhaled corticosteroids. Arrows indicate onset of typical 
asthma.
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Longitudinal change in bronchial responsiveness in patients with cough variant asthma taking or not taking long-term inhaled  corticosteroids Figure 2
Longitudinal change in bronchial responsiveness in patients with cough variant asthma taking or not taking long-term inhaled 
corticosteroids. Closed triangles indicate patients developing typical asthma. ***p < 0.0001.
Longitudinal change in cough reflex sensitivity in patients with cough variant asthma taking or not taking long-term inhaled  corticosteroids Figure 3
Longitudinal change in cough reflex sensitivity in patients with cough variant asthma taking or not taking long-term inhaled cor-
ticosteroids. Closed triangles indicate patients developing typical asthma.
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intervention against typical asthma onset from cough var-
iant asthma.
The present study clearly showed that bronchial respon-
siveness did not change after relief of cough without use
of ICS, and long-tem ICS attenuated bronchial respon-
siveness to inhaled methacholine in patients with cough
variant asthma, probably resulting in prevention of devel-
opment of typical asthma from cough variant asthma.
There were only 3 patients developing typical asthma
whose bronchial responsiveness was more increased
among the patients not taking ICS and was not obviously
increased after the asthma onset as shown in Fig. 1. These
findings suggest that an increased bronchial responsive-
ness at presentation may be a risk factor for asthma devel-
opment from cough variant asthma whereas further
increase in bronchial responsiveness may not be necessary
for the asthma onset. It is unclear why only coughing
occurs and additional wheezing appears without change
in bronchial hyperresponsiveness in this eosinophilic air-
way disorder.
It has been shown that early induction of ICS within 2
years following asthma onset is beneficial to achieve both
control of symptom and improvement of pulmonary
function and bronchial responsiveness in asthma [18].
Although number of patients taking long-term ICS was
small in this study, there was no significant influence of
duration of illness before induction of ICS on the degree
of improvement of bronchial responsiveness. Niimi et al
[19] have shown that airway remodelling exists but the
extent is smaller in cough variant asthma than in typical
asthma. This is likely to be responsible for the lack of
influence of ill duration on effect of ICS on bronchial
responsiveness. Further studies are needed to clarify this
issue.
Although other researchers have reported that cough
reflex sensitivity was heightened and recovered to a nor-
mal level following successful treatments of cough variant
asthma [20-23], it should be recognized that cough reflex
sensitivity is entirely independent of bronchial respon-
siveness [11] or bronchomotor tone [12], and that it is
within normal limits in stable typical asthma [10]. We
previously showed that 14 of 64 non-asthmatic healthy
subjects (21.9%) had bronchial hyperresponsiveness
when PC20-FEV1 of 10 mg/ml or less was defined as
bronchial hyperresponsiveness [24]. In another of our
studies [11], a C5 of 1.95 µM or less, 3.9 µM or less, and
7.8 µM or less was seen in 4 (5.6%), 14 (19.7%), and 31
(43.7%) of 71 non-asthmatic healthy subjects, respec-
tively. Considering the proportion of subjects with bron-
chial hyperresponsiveness, it is considered that a C5 of 3.9
µM or less to be defined as cough reflex hypersensitivity.
Longitudinal change in forced expiratory volume in one second (FEV1) in patients with cough variant asthma taking or not tak- ing long-term inhaled corticosteroids Figure 4
Longitudinal change in forced expiratory volume in one second (FEV1) in patients with cough variant asthma taking or not tak-
ing long-term inhaled corticosteroids. Closed triangles indicate patients developing typical asthma.
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Thus, in the present study, cough reflex sensitivity was
judged to be increased at initial presentation in 2 of 8
patients (25%) not taking ICS and 6 of 12 patients (50%)
receiving ICS. These findings are not consistent with our
previous findings that cough reflex sensitivity was within
normal limits in cough variant asthma [4,5,7,10].
Nevertheless cough reflex sensitivity did not change after
relief of cough despite use of ICS in the present study,
confirming our previous findings that cough reflex sensi-
tivity did not change following successful treatment of
cough variant asthma [7]. Taken together, it can be con-
cluded that cough reflex sensitivity is not involved in the
mechanism of cough in cough variant asthma even when
it is increased. In other words increased cough reflex sen-
sitivity is not a primary feature of cough variant asthma
and ICS does not affect the sensitivity. We do not know
why eosinophilic airway inflammation does increase
cough reflex sensitivity in atopic cough but not in cough
variant asthma. Precise interaction between eosinophilic
airway inflammation and cough reflex sensitivity should
be disclosed by future studies.
Early induction of ICS within 2 years following asthma
onset has been shown to be beneficial in attenuating
bronchial hyperresponsiveness as well as achieving both
control of symptom and improvement of pulmonary
function [18]. In this study, the degree of reduction of
bronchial hyperresponsiveness with ICS did not correlate
with the duration between onset of cough and induction
of ICS. It is not consist with the above-mentioned result
on asthma [18]. A possible explanation of this discrep-
ancy may be that airway remodelling increasing bronchial
responsiveness such as subepithelial fibrosis and smooth
muscle hypertrophy does not develop or become more
severe as the duration of illness is longer, while thickening
of subepithelial layer has been demonstrated in cough
variant asthma [19]. This possibility needs to be clarified
in future studies.
Conclusion
The present retrospective study showed that bronchial
hyperresponsiveness and cough reflex sensitivity did not
change after relief of cough when ICS therapy was not
taken in patients with cough variant asthma. A median of
2 years ICS treatment attenuated bronchial hyperrespon-
siveness, but not cough reflex sensitivity. Bronchial
responsiveness did not further increase after onset of typ-
ical asthma in 3 patients not taking ICS. These findings
suggest that long-term ICS treatment may prevent onset of
typical asthma from cough variant asthma by reducing
bronchial hyperresponsiveness, and that cough reflex sen-
sitivity is not involved in mechanism of cough in cough
variant asthma. Further studies including randomized
placebo-controlled studies are needed to confirm the pre-
ventive effect of long-term ICS on typical asthma onset
from cough variant asthma.
List of abbreviations
ANOVA = analysis of variance, C5 = provocative concen-
tration of capsaicin eliciting 5 or more coughs, CVA =
Relationship between duration of illness before induction of  inhaled corticosteroids and degree of improvement of bron- chial hyperresponsiveness in patients with cough variant  asthma taking long-term inhaled corticosteroids Figure 5
Relationship between duration of illness before induction of 
inhaled corticosteroids and degree of improvement of bron-
chial hyperresponsiveness in patients with cough variant 
asthma taking long-term inhaled corticosteroids.
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cough variant asthma, FEV1 = forced expiratory volume in
one second, FVC = forced vital capacity, GSEM = geomet-
ric standard error of the mean, ICS = inhaled corticoster-
oids, PC20-FEV1 = provocative concentration of
methacholine causing a 20% fall in forced expiratory vol-
ume in one second, SD = standard deviation,.
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